包装: | 1mg |
规格: | 98% |
市场价: | 10584元 |
分子量: | N/A |
Background:
Ibalizumab (TMB-355) is a humanised IgG4 monoclonal antibody that prevents HIV cell entry by binding to CD4 receptor. Ibalizumab has the potential for HIV-1 infection research[1].
[1]. Anthony Markham. Ibalizumab: First Global Approval. Drugs. 2018 May;78(7):781-785.
Protocol:
HIV-1
|